Explore Pfizer’s Multiple Myeloma Clinical Trials as potential treatment options for your patients 

  • [Recruiting]

MagnetisMM-4 

For patients with multiple myeloma 
Clinicaltrials.gov
Clinicaltrialsregister.eu
A Phase 1b/2 open-label umbrella study assessing the investigational medicine, elranatamab, in combination with other anticancer treatments in patients with multiple myeloma.
Study details
MagnetisMM-4 (MM4) is an umbrella study comprised of 2 sub-studies researching elranatamab, a bi-specific antibody, in combination with other anticancer treatments in patients with multiple myeloma (MM). This umbrella study aims to evaluate the safety and efficacy of combinations of elranatamab with other anticancer therapies in the treatment of patients with MM. 
Sub-study A 
Sub-study A is a Phase 1b/2, open-label study which aims to evaluate the safety and efficacy of elranatamab in combination with nirogacestat in patients with relapsed/refractory multiple myeloma (RRMM). 
Participants will be assigned to participate in one of two parts of the sub-study.  
  • Phase 1b aims to evaluate the safety and tolerability of elranatamab in combination with nirogacestat as well as select a recommended dose for the combination for Phase 2.
  • Phase 2 aims to further evaluate the efficacy and safety of the combination of elranatamab and nirogacestat. 
Whether participating in Phase 1b or Phase 2, all participants will receive elranatamab in combination with nirogacestat during their treatment period.  
MM4 Sub-study A aims to enrol about [80] participants, at about [12] research sites in approximately [2] countries. This study could last at least [2] years.

Participant eligibility*

  • Key inclusion criteria:
  • Relapsed/refractory multiple myeloma with at least 3 prior lines of therapy.
  • Refractory to at least one IMiD, one proteasome inhibitor, and one anti-CD38 antibody.
  • Measurable disease defined by at least one of the following:
    • Serum M-protein ≥ 0.5 g/dL by SPEP
    • Urinary M-protein excretion ≥ 200 mg/24 hours by UPEP
    • Serum immunoglobulin FLC ≥ 10 mg/dL (≥ 100 mg/L) AND abnormal serum immunoglobulin kappa to lambda FLC ratio.
  • ECOG performance status 0 -1.
  • Key exclusion criteria:
  • Participants with one of the following diagnoses may not qualify: 
    • Active plasma cell leukemia. 
    • Amyloidosis. 
    • Stem cell transplant with 12 weeks prior to enrollment, or active GVHD. 
    • POEMS syndrome. 
*Other inclusion and exclusion criteria apply. Please click on the following link to review all additional criteria.  
Additional criteria
To find out more, please visit cancer.pfizer.com
To find out more, complete the Contact Form and a Pfizer Field Medical representative will be in touch to discuss the details of the study and how to refer potentially eligible patients.
Learn more
Learn more
Thank you for considering this clinical trial for your patients.
  • [Recruiting]

MagnetisMM-6 

For transplant-ineligible patients with newly diagnosed multiple myeloma 
Clinicaltrials.gov
Clinicaltrialsregister.eu
A Phase 3, open-label study comparing the investigational medicine, elranatamab, in combination with other anticancer treatments versus an approved combination therapy in transplant-ineligible patients with newly diagnosed multiple myeloma. 
Study details
MagnetisMM-6 (MM6) is a Phase 3, open-label, randomized study evaluating the efficacy of elranatamab in combination with other anticancer treatments versus the control therapy in stem cell transplant-ineligible adults with newly diagnosed multiple myeloma. 

The trial is divided into two distinct parts: Part 1 and Part 2.  

Part 1 recruitment is completed, and Part 2 is currently recruiting. 

For Part 2, approximately 870 people with newly diagnosed multiple myeloma who are transplant-ineligible are expected to participate. Participants will be randomized in a 1:1 ratio, with half receiving the investigational medicine combination of elranatamab, daratumumab, and lenalidomide and half receiving the control therapy combination of daratumumab, lenalidomide, and dexamethasone. 

MM6 aims to enrol about [966] participants, in about [241] research sites in approximately [29] countries. This study could last at least [2] years.

Participant eligibility*

  • Key inclusion criteria:
  • Adults with prior diagnosis of MM as defined by IMWG criteria.  
  • Measurable disease based on IMWG criteria as defined by at least 1 of the following: 
    • Serum M-protein ≥0.5 g/dL by SPEP  
    • Urinary M-protein excretion ≥200 mg/24 hours by UPEP 
    • Serum immunoglobulin FLC ≥10 mg/dL (≥100 mg/L) AND abnormal serum immunoglobulin kappa to lambda FL ratio (<0.26 or >1.65).
  • Participants with NDMM that are transplant-ineligible as defined by age ≥65 years or transplant-ineligible as defined by age <65 years with comorbidities impacting the possibility of transplant. 
  • Eastern Cooperative Oncology Group (ECOG) performance status ≤2.  
  • Key exclusion criteria:
    Participants with one of the following diagnoses may not qualify:

    • Smoldering Multiple Myeloma. 
    • Monoclonal gammopathy of undetermined significance. 
    • Waldenströms Macroglobulinemia. 
    • Plasma cell leukemia. 
*Other inclusion and exclusion criteria apply. Please click on the following link to review all additional criteria.  
Additional criteria
To find out more, please visit cancer.pfizer.com
To find out more, complete the Contact Form and a Pfizer Field Medical representative will be in touch to discuss the details of the study and how to refer potentially eligible patients.
Learn more
Learn more
Thank you for considering MM6 for your patients.
  • [Recruiting]

MagnetisMM-7

For patients newly diagnosed with multiple myeloma 
C4891006 TACTIVE-U SSA C4891023 TACTIVE-U SSB C4891024 TACTIVE-U SSC
Clinicaltrials.gov
Clinicaltrials.gov
Clinicaltrialsregister.eu
A Phase 3, open-label, parallel, randomized, 2-arm study of elranatamab versus lenalidomide in patients newly diagnosed with multiple myeloma who have undergone autologous stem-cell transplantation.  
Study details
MagnetisMM-7 (MM7) is a Phase 3, open-label, parallel, randomized, 2-arm study comparing the efficacy of elranatamab versus lenalidomide in adults with newly diagnosed multiple myeloma (NDMM) post-autologous stem cell transplant (ASCT). 
Patients will be randomly assigned to Arm C (elranatamab) or Arm B (lenalidomide) of the trial. Cycle lengths will be 28 days each. Arm A (elranatamab) is fully enrolled. Arm C (elranatamab) and Arm B (lenalidomide) are currently enrolling.  

Arm C:

The study team will administer each dose of elranatamab as a subcutaneous injection. Patients will receive 2 priming doses of elranatamab during the first week. If well-tolerated, patients will receive elranatamab as a full dose every two weeks. Depending on their response to the treatment, the dosing interval for the injection will be reduced to receive elranatamab every four weeks.

Arm B:

Patients will take one capsule of lenalidomide by mouth, once daily, over repeated 28-day cycles.  
MM7 aims to enrol about [760] participants, at about [203] research sites in approximately [33] countries. This study could last up to [5] years.

Participant eligibility*

  • Key inclusion criteria:
  • Diagnosis of MM as defined according to IMWG criteria (Rajkumar, 2014) with measurable disease at diagnosis. 
  • MRD negative or MRD positive.
  • History of induction therapy for NDMM, followed by high dose therapy and ASCT. Randomization must occur within 120 days from the stem cell transplant. For participants who receive consolidation therapy after ASCT, randomization must occur within 60 days of consolidation and within 7 months from ASCT.  
  • Partial Response (PR) or better according to IMWG criteria at the time of randomization. 
  • Key exclusion criteria:
    Participants with one of the following diagnoses or criteria may not qualify: 
    • Plasma cell leukemia. 
    • Amyloidosis, Waldenström’s macroglobulinemia, or polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, skin changes (POEMS) syndrome. 
    • Known active central nervous system (CNS) involvement or clinical signs of myelomatous meningeal involvement. 
    • Previous MM maintenance treatment. 
*Other inclusion and exclusion criteria apply. Please click on the following link to review all additional criteria.  
Additional criteria
To find out more, please visit cancer.pfizer.com
To find out more, complete the Contact Form and a Pfizer Field Medical representative will be in touch to discuss the details of the study and how to refer potentially eligible patients.
Learn more
Learn more
Thank you for considering MM7 for your patients.
  • [Recruiting]

MagnetisMM-20

For patients with relapsed/refractory multiple myeloma
Clinicaltrials.gov
Clinicaltrialsregister.eu
A Phase 1b, open-label study of elranatamab in combination with carfilzomib plus dexamethasone and elranatamab in combination with maplirpacept in patients with relapsed/refractory multiple myeloma. 
Study details
MagnetisMM-20 (MM20) is a Phase 1b, open-label, non-randomized study assessing the safety and tolerability of elranatamab in combination with carfilzomib and dexamethasone and elranatamab in combination with maplirpacept in patients with relapsed/refractory multiple myeloma (RRMM). 
There are three parts to the MM20 study:  

Part 1:

Dose Escalation will evaluate the tolerability and safety of elranatamab in combination with carfilzomib and dexamethasone to determine the Recommended Phase 2 Dose (RP2D) of the combination. 

PART 2A:

Dose Escalation will evaluate the tolerability and safety of maplirpacept monotherapy and maplirpacept in combination with elranatamab. 

PART 2B:

Randomized Dose Optimization will evaluate the tolerability and safety of elranatamab in combination with maplirpacept to determine the RP2D of the combination. 
MM20 aims to enrol about [90] participants, at about [16] research sites in approximately [2] countries.

Participant eligibility*

  • Key inclusion criteria:
  • Prior diagnosis of MM as defined by IMWG criteria.
  • Measurable diseased based on IMWG criteria as defined by at least 1 of the following:
    • Serum M-protein ≥0.5 g/dL by SPEP
    • Urinary M-protein excretion ≥200 mg/24 hours by UPEP
    • Serum immunoglobulin FLC ≥10 mg/dL (≥100 mg/L) AND abnormal serum immunoglobulin kappa to lambda FL ratio (<0.26 or >1.65).
  • Part 1: Received at least 1 but not more than 3 prior lines of therapy for multiple myeloma (induction therapy followed by stem cell transplant and consolidation/maintenance therapy will be considered as 1 line of therapy).
  • Part 2: Received at least 3 prior lines of therapy for multiple myeloma who are refractory to at least one IMiD, one PI and one anti-CD38 antibody. 
  • Key exclusion criteria:
    Participants with one of the following diagnoses or criteria may not qualify:

    • Plasma cell leukemia, smouldering MM, Waldenström’s macroglobulinemia, amyloidosis, POEMS Syndrome, primary refractory MM (defined as participants who have never achieved at least a MR with any treatment during the disease course).
    • Impaired cardiovascular function or clinically significant cardiovascular diseases.
    • Participants with any active, uncontrolled bacterial, fungal, or viral infection.
    • Stem cell transplant within 12 weeks prior to enrolment, or active graft versus host disease.
*Other inclusion and exclusion criteria apply. Please click on the following link to review all additional criteria.  
Additional criteria
To find out more, please visit cancer.pfizer.com
To find out more, complete the Contact Form and a Pfizer Field Medical representative will be in touch to discuss the details of the study and how to refer potentially eligible patients.
Learn more
Learn more
Thank you for considering MM20 for your patients.
  • [Recruiting]

MagnetisMM-30

For patients with relapsed/refractory multiple myeloma 
Clinicaltrials.gov
Clinicaltrialsregister.eu
A Phase 1b, open-label study of elranatamab in combination with iberdomide in participants with relapsed/refractory multiple myeloma 
Study details
MagnetisMM-30 (MM30) is a Phase 1b, open-label study evaluating the tolerability and safety of elranatamab in combination with iberdomide in patients with relapsed/refractory multiple myeloma (RRMM).  
The MM30 study is composed of two parts:  

Part 1:

Dose Escalation will evaluate the tolerability and safety of elranatamab in combination with iberdomide.  
Part 2:
Dose Randomization will further evaluate the overall safety of elranatamab in combination with iberdomide. 
Whether participating in Part 1 or Part 2, all participants will receive elranatamab in combination with iberdomide during their treatment period. Elranatamab will be administered as a subcutaneous injection. Iberdomide will be taken by mouth, once daily, for 21 days over a 28-day cycle. After 21 days, iberdomide will be stopped for 7 days before continuing the dosing routine each cycle.  
MM30 aims to enrol about [100] participants, at about [15] research sites in approximately [3] countries. This study will last at least [2] years.

Participant eligibility*

  • Key inclusion criteria:
  • Prior diagnosis of MM as defined according to IMWG criteria.  
  • Measurable disease based on IMWG criteria as defined by at least 1 of the following: 
    • Serum M-protein ≥0.5 g/dL by SPEP  
    • Urinary M-protein excretion ≥200 mg/24 hours by UPEP
    • Serum immunoglobulin FLC ≥10 mg/dL (≥100 mg/L) AND abnormal serum immunoglobulin kappa to lambda FLC ratio (<0.26 or >1.65). 
  • Part 1: Received 2-4 prior lines of therapy for multiple myeloma, consisting of at least 1 immunomodulatory drug and 1 proteasome inhibitor. 
  • Part 2: Received 1-3 prior lines of therapy for multiple myeloma, consisting of at least 1 immunomodulatory drug and 1 proteasome inhibitor. 
  • Key exclusion criteria:
    Participants with any of the following diagnoses or criteria may not qualify:  
    • Plasma cell leukemia, smouldering MM, Waldenström’s macroglobulinemia, amyloidosis, POEMS Syndrome. 
    • Impaired cardiovascular function or clinically significant cardiovascular diseases. 
    • Stem cell transplant within 12 weeks prior to enrolment or active graft vs host disease. 
    • Any other active malignancy within 3 years prior to enrolment, except for adequately treated basal cell or squamous cell skin cancer, or carcinoma in situ.  
*Other inclusion and exclusion criteria apply. Please click on the following link to review all additional criteria.  
Additional criteria
To find out more, please visit cancer.pfizer.com
To find out more, complete the Contact Form and a Pfizer Field Medical representative will be in touch to discuss the details of the study and how to refer potentially eligible patients.
Learn more
Learn more
Thank you for considering MM30 for your patients.
  • [Recruiting]

MagnetisMM-32

For patients with relapsed/refractory multiple myeloma who received prior anti-CD38 directed therapy  
Clinicaltrials.gov
Clinicaltrialsregister.eu
A Phase 3, open-label study of elranatamab monotherapy versus elotuzumab, pomalidomide, dexamethasone (EPd) or pomalidomide, bortezomib, dexamethasone (PVd) or carfilzomib and dexamethasone (Kd) in patients with relapsed/refractory multiple myeloma who have received prior anti-CD38 directed therapy.  
Study details
MagnetisMM-32 (MM32) is a Phase 3, open-label study evaluating whether elranatamab monotherapy can provide superior clinical benefit compared with Elotuzumab, Pomalidomide, Dexamethasone (EPd), Pomalidomide, Bortezomib, Dexamethasone (PVd), or Carfilzomib and Dexamethasone (Kd) in patients with relapsed/refractory multiple myeloma (RRMM) who have received at least 1 but not more than 4 prior lines of therapy including lenalidomide and anti-CD38 targeting therapies.  
Arm A: Elranatamab  
Patients will receive elranatamab by subcutaneous injection. Elranatamab will be administered in 28-day cycles at the study clinic. The first dose of elranatamab will require overnight hospitalisation (approximately 2 days). Patients will receive the second dose of elranatamab approximately 3 days after the first. Patients will then receive doses weekly followed by less frequent dosing (eg, once every two weeks, then monthly) during the course of treatment period. 
Arm B: EPd or PVd or Kd (investigator’s choice of therapy (ICT))  

EPd: this combination includes three medications (elotuzumab, pomalidomide and dexamethasone) that will be administered in 28-day cycles. Patients will receive elotuzumab by intravenous infusion at the study clinic. Patients will take dexamethasone and pomalidomide by mouth.  

PVd: this combination includes three medications (pomalidomide, bortezomib, and dexamethasone) that will be administered in 21-day cycles. Patients will receive bortezomib by subcutaneous injection or intravenous infusion at the study clinic. Patients will take dexamethasone and pomalidomide by mouth.   

Kd: this combination includes two medications (carfilzomib and dexamethasone) that will be administered in 28-day cycles. Patients will receive carfilzomib by intravenous infusion at the study clinic. Patients will take dexamethasone by mouth. 

MM32 aims to enrol about [492] participants, at about [150-180] research sites in approximately [20] countries. This study will last about [5] years.

Participant eligibility*

  • Key inclusion criteria:
  • Prior diagnosis of MM per IMWG criteria and previously received 1 to 4 prior lines of therapy including prior anti-cluster of differentiation 38 (CD38) antibody and prior lenalidomide.
  • Documented evidence of progressive disease or failure to achieve a response to last line of therapy per IMWG criteria.
  • Measurable disease defined as at least 1 of the following:
    1. Serum M-protein ≥0.5 g/dL;
    2. Urinary M-protein excretion ≥200 mg/24 hours;
    3. Serum involved immunoglobulin FLC ≥10 mg/dL AND abnormal serum immunoglobulin kappa to lambda FLC ratio (<0.26 or >1.65).
  • Have clinical laboratory values within the specified range.
  • Key exclusion criteria:
    Participants with any of the following diagnoses may not qualify: 
    • Smoldering multiple myeloma. 
    • Plasma cell leukemia. 
    • Amyloidosis. 
    • Polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy and skin abnormalities (POEMS) syndrome. 
*Other inclusion and exclusion criteria apply. Please click on the following link to review all additional criteria.  
Additional criteria
To find out more, please visit cancer.pfizer.com
To find out more, complete the Contact Form and a Pfizer Field Medical representative will be in touch to discuss the details of the study and how to refer potentially eligible patients.
Learn more
Learn more
Please speak to the study team or a Pfizer Field Medical representative for the full eligibility criteria.
Thank you for considering MM32 for your patients.

Connect with a Pfizer trial site 

Pfizer’s Multiple Myeloma Clinical Trials are taking place at research sites in multiple countries worldwide. 
To find your nearest study site, please enter your postal code and select the optimal distance to view on the map from the drop-down menu: 

      Thank you for considering Pfizer’s Multiple Myeloma Clinical Trials for your patients.